• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.

作者信息

Piccerillo Alfredo, El Hachem Maya, De Vito Rita, De Luca Erika Valentina, Peris Ketty

机构信息

Institute of Dermatology, Università Cattolica del Sacro Cuore, Milan, Italy.

Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

出版信息

JAMA Dermatol. 2020 Jun 1;156(6):708-710. doi: 10.1001/jamadermatol.2020.0304.

DOI:10.1001/jamadermatol.2020.0304
PMID:32320041
Abstract
摘要

相似文献

1
Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.帕博利珠单抗治疗多发性皮肤鳞状细胞癌合并隐性营养不良性大疱性表皮松解症患者
JAMA Dermatol. 2020 Jun 1;156(6):708-710. doi: 10.1001/jamadermatol.2020.0304.
2
Combined anti-inflammatory and low-dose antiproliferative therapy for squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.联合抗炎和低剂量抗增殖疗法治疗隐性营养不良性大疱性表皮松解症中的鳞状细胞癌。
J Eur Acad Dermatol Venereol. 2020 Jan;34(1):e1-e3. doi: 10.1111/jdv.15835. Epub 2019 Sep 2.
3
Targeting the Jak/Signal Transducer and Activator of Transcription 3 Pathway with Ruxolitinib in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa-Squamous Cell Carcinoma.在隐性营养不良性大疱性表皮松解症-鳞状细胞癌小鼠模型中用鲁索替尼靶向Jak/信号转导子和转录激活子3通路
J Invest Dermatol. 2021 Apr;141(4):942-946. doi: 10.1016/j.jid.2020.08.022. Epub 2020 Oct 16.
4
Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.西米普利单抗治疗重度隐性营养不良性大疱性表皮松解症患者的鳞状细胞癌
J Dtsch Dermatol Ges. 2023 Mar;21(3):295-297. doi: 10.1111/ddg.14980. Epub 2023 Feb 28.
5
Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.西妥昔单抗在隐性营养不良性大疱性表皮松解症伴鳞状细胞癌中作为放疗和手术辅助药物的应用。
Br J Dermatol. 2013 Jul;169(1):208-10. doi: 10.1111/bjd.12272.
6
Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa.在患有先天隐性营养不良性大疱性表皮松解症的年轻患者中，西普单抗治疗局部晚期皮肤鳞状细胞癌取得良好临床反应。
Acta Dermatovenerol Alp Pannonica Adriat. 2024 Sep;33(3):145-149.
7
Understanding the pathogenesis of recessive dystrophic epidermolysis bullosa squamous cell carcinoma.了解隐性营养不良型大疱性表皮松解症鳞状细胞癌的发病机制。
Dermatol Clin. 2010 Jan;28(1):171-8. doi: 10.1016/j.det.2009.10.023.
8
A recurrent nonsense mutation occurring as a de novo event in a patient with recessive dystrophic epidermolysis bullosa.在一名隐性营养不良型大疱性表皮松解症患者中作为新生事件出现的复发性无义突变。
Dermatology. 2011;223(3):219-21. doi: 10.1159/000330331. Epub 2011 Aug 18.
9
Canakinumab in recessive dystrophic epidermolysis bullosa: a novel unexpected weapon for non-healing wounds?卡那单抗治疗隐性营养不良性大疱性表皮松解症：治疗难愈合伤口的新型意外武器？
Clin Exp Rheumatol. 2016 Sep-Oct;34(5):961-962. Epub 2016 Feb 9.
10
De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa.隐性营养不良型大疱性表皮松解症患者的新发抗VII型胶原蛋白抗体
J Invest Dermatol. 2014 Apr;134(4):1138-1140. doi: 10.1038/jid.2013.475. Epub 2013 Nov 8.

引用本文的文献

1
Taking care of patients with recessive dystrophic epidermolysis bullosa from birth to adulthood: a multidisciplinary Italian Delphi consensus.从出生到成年照顾隐性营养不良性大疱性表皮松解症患者：意大利多学科德尔菲共识
Orphanet J Rare Dis. 2025 Mar 16;20(1):128. doi: 10.1186/s13023-025-03635-1.
2
Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases.隐性营养不良型大疱性表皮松解症皮肤鳞状细胞癌的治疗：157 例系统性回顾。
Orphanet J Rare Dis. 2024 May 21;19(1):206. doi: 10.1186/s13023-024-03190-1.
3
Epidermolysis-Bullosa-Associated Squamous Cell Carcinomas Support an Immunosuppressive Tumor Microenvironment: Prospects for Immunotherapy.
大疱性表皮松解症相关鳞状细胞癌支持免疫抑制性肿瘤微环境：免疫治疗的前景
Cancers (Basel). 2024 Jan 22;16(2):471. doi: 10.3390/cancers16020471.
4
Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre.晚期皮肤鳞状细胞癌中的免疫检查点抑制剂：来自加拿大综合癌症中心的真实世界经验。
Cancers (Basel). 2023 Aug 29;15(17):4312. doi: 10.3390/cancers15174312.
5
Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.两名隐性营养不良型大疱性表皮松解症患者晚期多发性皮肤鳞状细胞癌的免疫治疗结果不同。
Acta Derm Venereol. 2023 Jun 20;103:adv4870. doi: 10.2340/actadv.v103.4870.
6
Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature.遗传性大疱性表皮松解症患者的鳞状细胞癌：文献复习。
Cells. 2022 Apr 17;11(8):1365. doi: 10.3390/cells11081365.
7
Investigational Treatments for Epidermolysis Bullosa.表皮松解性水疱症的治疗研究。
Am J Clin Dermatol. 2021 Nov;22(6):801-817. doi: 10.1007/s40257-021-00626-3. Epub 2021 Jul 22.
8
Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.大疱性表皮松解症相关皮肤鳞癌：28 年回顾性研究。
Acta Derm Venereol. 2021 Aug 24;101(8):adv00523. doi: 10.2340/00015555-3875.
9
Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy.免疫治疗时代的皮肤鳞状细胞癌
Cancers (Basel). 2021 Mar 8;13(5):1148. doi: 10.3390/cancers13051148.
10
Translational perspectives to treat Epidermolysis bullosa-Where do we stand?治疗大疱性表皮松解症的转化医学视角——我们目前的进展如何？
Exp Dermatol. 2020 Nov;29(11):1112-1122. doi: 10.1111/exd.14194.